The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Typhoid Vi Polysaccharide Vaccine Market Increase Between 2026 And 2030?
The typhoid Vi polysaccharide vaccine market size has experienced rapid growth in recent years. It is projected to expand from $6.71 billion in 2025 to $7.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 18.1%. The historical increase can be attributed to the expansion of national immunization schedules, increased awareness regarding typhoid prevention, the availability of polysaccharide vaccine formulations, the growth of public vaccination campaigns, and support from global health organizations.
The typhoid Vi polysaccharide vaccine market is projected for rapid expansion over the coming years, forecast to reach $15.51 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.3%. This projected growth stems from several factors, including an intensified focus on mass immunization in endemic areas, increased investments in vaccine manufacturing capacity, the expansion of adult vaccination initiatives, a greater emphasis on travel-related immunization, and the adoption of enhanced vaccine storage technologies. Key trends during this period are expected to encompass a rise in government-backed immunization schemes, surging demand for pediatric vaccination coverage, a heightened focus on preventive healthcare measures, the broadening of public-private vaccine distribution frameworks, and an amplified emphasis on optimizing the cold chain.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp
Which Drivers Are Advancing The Typhoid Vi Polysaccharide Vaccine Market Growth?
The rising prevalence of typhoid is anticipated to stimulate the growth of the typhoid Vi polysaccharide vaccine market in the future. Typhoid, a potentially fatal infection caused by the bacteria Salmonella Typhi, typically spreads through contaminated food or drink. The increase in typhoid cases is attributed to poor sanitation, unsafe water sources, rapid urbanization, and greater exposure to tainted food and water. The typhoid Vi polysaccharide vaccine market supports this trend by offering immunization for adults and children aged 2 years and older, providing protective immunity against Salmonella enterica serovar Typhi and reducing the burden of typhoid fever in endemic regions. For instance, in August 2024, data released by the UK Health Security Agency indicated a rise in laboratory-confirmed symptomatic enteric fever cases in England, Wales, and Northern Ireland, with S. Typhi reaching 313 cases, S. Paratyphi A reaching 135 cases, and S. Paratyphi B reaching 18 cases. Thus, the increasing incidence of typhoid is driving the expansion of the typhoid Vi polysaccharide vaccine market.
How Is Segment Classification Applied In The Typhoid Vi Polysaccharide Vaccine Market?
The typhoid vi polysaccharide vaccine market covered in this report is segmented –
1) By Type: Child, Adult
2) By Route Of Administration: Oral, Parenteral
3) By Application: Government Institution, Private Sector, Other Applications
Subsegments:
1) By Child: Pediatric Formulations, Age-Specific Dosages
2) By Adult: Standard Adult Formulations, High-Risk Population Formulations
What Trends Are Affecting The Typhoid Vi Polysaccharide Vaccine Market Dynamics?
Prominent companies active in the typhoid antibody testing market are prioritizing the creation of advanced products, including molecular diagnostic tests, to boost the precision and speed of typhoid fever diagnosis. Molecular diagnostic tests exhibit high sensitivity and specificity, facilitating the accurate and quick identification of pathogens like Salmonella Typhi in instances of typhoid fever. For example, in April 2023, Vanguard Diagnostics, a diagnostic reagent developer based in India, unveiled the VANSCAN typhoid RT PCR test, a molecular diagnostic solution utilizing its patented technology. This test is designed to detect and diagnose typhoid fever through a real-time PCR (RT-PCR) testing method, which provides enhanced accuracy and sensitivity over conventional serological tests. The VANSCAN Typhoid RT PCR Test signifies a major progression in typhoid diagnostics, setting a new gold standard for prompt, accurate, and dependable disease detection within India and globally.
Which Key Players Are Active In The Typhoid Vi Polysaccharide Vaccine Market?
Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., Merck & Co. Inc., PT Bio Farma, Bharat Biotech International Limited, Bio-Med Pvt. Ltd., Hualan Biological Engineering Inc., Indian Immunologicals Limited, Serum Institute of India Limited, Biological E Limited, Panacea Biotec Limited, Zydus Lifesciences Limited, Beijing Minhai Biotechnology Co. Ltd., Lanzhou Institute of Biological Products Co. Ltd., Chengdu Institute of Biological Products Co. Ltd., Wuhan Institute of Biological Products Co. Ltd., Eubiologics Co. Ltd., Incepta Vaccine Limited, GC Pharma, KM Biologics Inc., Bharat Immunologicals and Biologicals Corporation Limited, Sinovac Biotech Ltd., Bio Farma Indonesia
Access The Complete Typhoid Vi Polysaccharide Vaccine Market Report:
Which Region Has The Strongest Presence In The Typhoid Vi Polysaccharide Vaccine Market?
Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2025. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Typhoid Vi Polysaccharide Vaccine Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=8313&type=smp
Browse Through More Reports Similar to the Global Typhoid Vi Polysaccharide Vaccine Market 2026, By The Business Research Company
Preventive Vaccines Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report
Vaccines Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report
Chickenpox Vaccine Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model